Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Depression

    Boston, MA

    Search
    Depression
    Boston, MA
    Show Map
    Map View
    Boston, MA
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      170 Depression Trials near Boston, MA

      Power is an online platform that helps thousands of Depression patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Lurasidone for Cognitive Improvement in Bipolar Disorder

      Boston, Massachusetts
      This trial is testing whether lurasidone can help improve thinking and memory in people with bipolar disorder who are currently stable but have cognitive problems. The medication works by balancing brain chemicals. Lurasidone has shown potential in improving thinking and memory in both schizophrenia and bipolar disorder.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Age:19 - 65

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      150 Participants Needed

      Active on Power

      Fasedienol Nasal Spray for Social Anxiety Disorder

      Boston, Massachusetts
      This Phase 3 clinical trial is designed to evaluate the Fasedienol Nasal Spray (fasedienol) for adults that are 18-65 who suffer from symptoms of social anxiety such as nervousness, worry or fear of judgement. In addition, there is an Open Label Extension phase of the study for patients that choose to participate where use of nasal spray for up to 12 months will be assessed.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Bipolar, Schizophrenia, Alcohol Use, Others
      Must Not Be Taking:Psychotropics, CBD, Herbal

      236 Participants Needed

      Aticaprant + Antidepressant for Depression

      Boston, Massachusetts
      The purpose of this study is to assess how well aticaprant works compared to placebo when given in addition to antidepressant therapy (selective serotonin reuptake inhibitor \[SSRI\] or serotonin-norepinephrine reuptake inhibitor \[SNRI\]) in preventing return of depression symptoms in participants with major depressive disorder who experience a loss of interest and pleasure and who achieve a stable response after treatment with adjunctive aticaprant.
      Stay on current meds
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:18 - 64

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      660 Participants Needed

      Ketamine for Depression

      Boston, Massachusetts
      Subanesthetic dose of intravenous ketamine (KET) has been found to be highly effective in rapid treatment depression and associated suicidality but its exact mechanism of remains uncertain. This study will use a novel approach to elucidate KET's effects on the molecular/ gene expression pathways in living neurons obtained from the olfactory epithelium and correlate the changes to rapid improvement in depression via changes in the brain connectome. The study will identify the molecular targets and pathways involved in KET'S mechanism of rapid clinical action and pave the way for development of novel, more efficacious, and safer therapeutic agents.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 1
      Age:18 - 50

      Key Eligibility Criteria

      Disqualifiers:Bipolar, Schizophrenia, Substance Use, Others
      Must Not Be Taking:Psychotropics, Fluoxetine

      120 Participants Needed

      Mind-body Resilience Program for Cardiac Arrest

      Boston, Massachusetts
      The purpose of this study is to pilot two resilience interventions for cardiac arrest survivors and their informal caregivers, Recovering Together after Cardiac Arrest 1 and Recovering Together after Cardiac Arrest 2 . The data the investigators gather in this study will be used to further refine the interventions.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Psychosis, Mania, Substance Dependence, Others

      84 Participants Needed

      Smartphone CBT for Psoriasis and Depression

      Boston, Massachusetts
      A single arm, pilot study in which all eligible participants will be enrolled in an 8-week coach-guided smartphone delivered CBT program. The full duration of the program, with follow-up interview, will be 9 weeks.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Previous CBT, Psychotherapy, Suicide Risk, Others

      30 Participants Needed

      Machine Learning-Optimized Digital Therapy for Emotional Disorders

      Boston, Massachusetts
      This trial aims to improve digital mental health treatments for Kaiser Permanente members by using machine learning to recommend the best program for each person. Participants will be placed in one of three online mental health programs and receive ongoing support. The goal is to find out which program works best for different people.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Non-English Speakers, Under 18

      1800 Participants Needed

      FIRST Psychotherapy for Youth Mental Health Issues

      Cambridge, Massachusetts
      The study will compare the impact FIRST (a transdiagnostic treatment built upon five empirically supported principles of change) versus usual care outpatient psychotherapy on youths' mental health outcomes and a candidate mechanism of change: regulation of negative emotions.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:7 - 15

      Key Eligibility Criteria

      Disqualifiers:Suicide Risk, Eating Disorder, Schizophrenia, Autism, Others

      212 Participants Needed

      Deep Brain Stimulation for Neurological and Psychiatric Conditions

      Charlestown, Massachusetts
      We propose to study approach/avoidance behavior as measured by the Approach Avoidance task in 20 epilepsy patients undergoing implementation of depth electrodes for seizure monitoring in the Epilepsy Monitoring Unit at MGH. We will also study the effects of VC/VS electrical stimulation on approach-avoidance conflict in 20 adult patients who have undergone DBS implantation for severe MDD and/or OCD. There are 100-200 patients in the world with DBS electrodes in the VC/VS, and our research team cares for more than any other institution. Both participant groups will be assessed with respect to reward-aversion decision conflict using the task. The task will be performed with concurrent EEG recordings in DBS patients, and with continuous recording through our invasive neurophysiology rig in EMU subjects.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting

      Key Eligibility Criteria

      Disqualifiers:Bipolar, Psychotic Disorder, Substance Abuse, Others

      60 Participants Needed

      Pramipexole vs Escitalopram for Depression in HIV

      Boston, Massachusetts
      A phase II, randomized, open-label, two-arm clinical trial evaluating the safety and efficacy of pramipexole extended release (ER) versus escitalopram for the treatment of major depressive disorder (MDD) and comorbid MDD with mild neurocognitive disorder (MND) in persons with HIV (PWH). Participants will be assessed comprehensively and briefly at intercurrent visits to monitor for toxicity, response to therapy, and to assess for dose changes. An optional sub-study to evaluate treatment impact on the cerebrospinal fluid (CSF) profile will be conducted in a subset of 36 participants.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Severe MDD, Psychotic Disorders, Alcohol Use, CAD, Others
      Must Be Taking:ART Regimen

      186 Participants Needed

      CBD for Chronic Low Back Pain

      Boston, Massachusetts
      This study will investigate whether cannabidiol (CBD), the primary centrally and peripherally active non-intoxicating compound in the cannabis plant, exerts anti-neuroinflammatory effects in patients with chronic low back pain (cLBP) with or without mild-to-moderate depression.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Neurological Illness, Major Psychiatric Illness, Others
      Must Not Be Taking:Immunosuppressants, CNS Depressants, Opioids, Others

      80 Participants Needed

      Pregnenolone for Depression in HIV

      Boston, Massachusetts
      This study will determine the effects of pregnenolone on brain function, inflammation and depressive symptoms in people with HIV who have depression. Participants in this study will receive a pill of either pregnenolone or placebo, and can stay on their current antidepression medications. Brain imaging and behavioral assessments will be performed during the study.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Severe Infections, Bipolar, Schizophrenia, Others
      Must Be Taking:Antidepressants

      120 Participants Needed

      Mindfulness-Based Cognitive Therapy for Chronic Pain and Depression

      Boston, Massachusetts
      The goal of this clinical trial is to pilot a randomized controlled trial comparing an adaptation of mindfulness-based cognitive therapy to the health enhancement program for chronic pain and depression. The main questions it aims to answer in a later fully powered randomized controlled trial are: * Is an adaptation of mindfulness-based cognitive therapy for older Black adults able to improve quality of life? * Will an adapted mindfulness based cognitive therapy reduce pain interference to a greater degree than a traditional health enhancement program?
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:50+

      Key Eligibility Criteria

      Disqualifiers:Severe Depression, Substance Abuse, Cognitive Impairment, Psychosis, Others

      60 Participants Needed

      Contingency Management for Depression and Cannabis Use

      Boston, Massachusetts
      The goal of this study is to disentangle relationships between acute cannabis use and withdrawal on proximal depression and suicide risk and recovery in adolescents ages 12-18 years by incorporating time-varying patterns of substance use, mood, and SI. This project aims to guide the development of scalable, individualized, accessible, and affordable interventions aimed to reduce depression and suicide risk among adolescents.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:12 - 18

      Key Eligibility Criteria

      Disqualifiers:Epilepsy, Cognitive Impairment, Others

      200 Participants Needed

      Digital Single Session Intervention for Youth Mental Health

      Boston, Massachusetts
      This trial tests an online program for kids aged 9-17 who are waiting for mental health treatment. The program teaches them to change negative behaviors by practicing positive ones, helping them feel better while they wait for therapy.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:9 - 17

      Key Eligibility Criteria

      Disqualifiers:Non-English Speaking, No Digital Device

      226 Participants Needed

      Resiliency & Burnout Interventions for Behavioral Health Staff

      Boston, Massachusetts
      The goal of this clinical trial is to compare Integrated Resiliency Training and Task Sharing (IRTTS) to Workplace Improvement Learning Collaborative (WILC) in group homes for adults with serious mental illness and/or intellectual and developmental disabilities. The main questions it aims to answer are: * Is IRTTS superior to WILC in improving residential care worker (RCW) resiliency; stress management and burnout; depression and anxiety; and positive health behaviors? * Is IRTTS superior to WILC in improving RCW turnover/retention; RCW sick days/absenteeism; and group home safety and resident incidents? * What are the barriers, facilitators, and resources required to successfully implement IRTTS and WILC? Participants may engage in training sessions, collaborate with residents and other RCWs in their group homes, attend meetings with RCWs from other group homes, complete surveys, participate in focus groups, and/or give qualitative interviews. Researchers will compare IRTTS to WILC to see which intervention should be implemented to achieve the greatest improvement in RCW resiliency and greatest reduction in burnout and turnover in group homes for adults with serious mental illness and/or developmental and intellectual disabilities.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Temp Staff, Per Diem Workers, Others

      900 Participants Needed

      PRISM for Cancer

      Boston, Massachusetts
      Multi-Site Randomized Controlled Trial testing the efficacy of the Promoting Resilience in Stress Management (PRISM) intervention among Adolescents and Young Adults with Advanced Cancer
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:12 - 24

      Key Eligibility Criteria

      Disqualifiers:Patient Refusal, Parent Refusal, Others

      195 Participants Needed

      Brief Cognitive Behavioral Therapy for PrEP Adherence in Pregnant Women

      Boston, Massachusetts
      Pregnant women in South Africa (SA) are at high risk of HIV acquisition. Pre-exposure prophylaxis (PrEP) use during pregnancy is both safe and effective in preventing HIV. However, posttraumatic stress (associated with intimate partner violence and/or other traumas) and depression negatively impact PrEP adherence among women in SA. Addressing posttraumatic stress and depression will likely improve PrEP adherence and persistence (i.e., sustained PrEP adherence over time) during pregnancy and breastfeeding, which are periods of dramatically increased HIV risk. The overarching goal of this proposal is to develop and test the feasibility and acceptability of a cognitive behavioral intervention that targets common underlying factors of posttraumatic stress and depression to improve PrEP adherence and persistence during pregnancy and the postpartum transition. The specific aims of the project are to (1) explore the mechanisms by which posttraumatic stress and depression impact PrEP adherence and persistence during pregnancy via qualitative interviews; (2) develop a brief PrEP adherence and persistence intervention (\~4 sessions) that reduces the negative impact of psychological mechanisms common to posttraumatic stress and depression on PrEP use, and builds behavioral skills to improve self-care; and (3) evaluate the feasibility, acceptability, and signals of preliminary efficacy of the intervention, which will be integrated into antenatal care, in a pilot randomized controlled trial. All data will be collected in the Midwife Obstetrics Unit (MOU) in Gugulethu, a peri-urban settlement and former township community outside of Cape Town, SA.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:15+
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Psychotic Disorder, Untreated Bipolar, Others
      Must Be Taking:PrEP

      108 Participants Needed

      Buspirone + Melatonin for Depression After Traumatic Brain Injury

      Charlestown, Massachusetts
      Traumatic brain injuries (TBIs) are common. Post-TBI depression is associated with anxiety, aggression, fatigue, distractibility, anger, irritability, and rumination. The current research group conducted a pilot clinical trial, which investigated the novel treatment combination of buspirone and melatonin (B+MEL) in outpatients with clinical depression. Compared to placebo, B+MEL was associated with a significant improvement in depressive symptoms. Depression following TBI may be different from clinical depression. The B+MEL combination has never been studied in patients with post-TBI depression. The B+MEL has shown promise in ameliorating cognitive difficulties in people with depression. Because cognitive problems are typical in people with post-TBI depression, we plan to measure the effect of the B+MEL combination on cognitive ability in post-TBI depression. Additionally, we are interested in measuring functional magnetic resonance imaging changes before and after treatment with B+MEL in order to gain insight into the brain mechanisms of our hypothesized clinical symptom changes. The goals of the proposed pilot research project are to assess changes in symptoms in patients with post-TBI depression following Buspirone + Melatonin combination (B+MEL), and the corresponding brain mechanisms underlying these hypothesized changes by measuring: 1) depressive symptoms; 2) cognitive symptoms; 3) functional magnetic resonance imaging.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:18 - 64

      Key Eligibility Criteria

      Disqualifiers:Neurological Disorders, Bipolar, Schizophrenia, Others
      Must Be Taking:Buspirone, Melatonin

      10 Participants Needed

      Psychological Treatment for Intrusive Thoughts

      Boston, Massachusetts
      The investigators are conducting this study to learn more about the cognitive and attentional processes among individuals with three types of repetitive negative thinking (RNT): mental rituals (as seen in obsessive compulsive disorder, OCD), worries (as seen in generalized anxiety disorder, GAD), and ruminations (as seen in major depressive disorder, MDD). Specifically, the investigators are studying whether psychological treatment can help people with RNT who have trouble stopping unwanted thoughts and shifting their attention.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Age:18 - 60

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      87 Participants Needed

      Why Other Patients Applied

      "I’ve had depression for many years and been on a LOT of different medications. They work for awhile and then they just stop working. It’s very frustrating. I am very open to trying something new and different. Just looking to fight this, head on."

      ZX
      Depression PatientAge: 55

      "Dealt with treatment-resistant depression for pretty much my entire life. I would be eternally grateful for something that actually worked for once. I'd just like to feel normal. "

      CM
      Depression PatientAge: 55

      "I have tried several different drugs and nothing seems to help really. I'm hoping this trial could give me my life back. I haven't tried anything like psilocybin yet... fingers crossed."

      MT
      Anxiety PatientAge: 59

      "I've been struggling with alcoholism and depression on-and-off for about 12 years. I have heard of people have good outcomes for various mental health issues after using psilocybin but would not be willing to try it without a doctor's care. So I'm applying to a trial. "

      QJ
      Depression PatientAge: 60

      "I have struggled with depression since I was a child. I have experienced about more than 6 major depressive episodes lasting at least 4 months since I was 7 years old. I have tried talk therapy, a plethora of medication, and nothing has worked long term. Medication and talk therapy helps me manage and reduce the length of depressive episodes but I am in search for alternative treatments. My depression has made completing a bachelors degree a major challenge."

      UD
      Depression PatientAge: 25
      Match to a Depression Trial

      BPL-003 for Treatment Resistant Depression

      Boston, Massachusetts
      This trial tests a nasal spray drug called BPL-003 along with counseling for people whose depression doesn't get better with usual treatments. The drug aims to quickly improve mood, and counseling helps provide emotional support.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Schizophrenia, Bipolar, Substance Use, Others
      Must Not Be Taking:Antidepressants

      196 Participants Needed

      Sertraline for PTSD

      Boston, Massachusetts
      This is a research study to examine the effectiveness of a brief screening method that may predict which people with posttraumatic stress disorder (PTSD) or depression are most likely to show a positive response to selective serotonin reuptake inhibitor (SSRI) medications. Participants will be recruited over approximately 5.25 years, until at least 94 participants complete the 17 week study.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Bipolar, Schizophrenia, Pregnancy, Others
      Must Be Taking:SSRIs

      94 Participants Needed

      PeersCOG for Geriatric Depression

      Boston, Massachusetts
      The purpose of this study is to assess the feasibility, acceptability, and fidelity of an 8-week intervention where peer coaches will deliver depression care to adults 60 years of age or older who have depression and subjective cognitive decline.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:60+

      Key Eligibility Criteria

      Disqualifiers:Mild Cognitive Impairment, Alzheimer's, Others

      30 Participants Needed

      Behavioral Health Program for Nursing Home Residents

      Boston, Massachusetts
      The goal of this clinical trial is to test a behavioral health program (Interventions for Stressful Transitions in Later Life, InSTILL) for skilled nursing facility residents and their primary support person. The main questions it aims to answer is whether the program is program is feasible, satisfactory, and helpful. The researchers will compare the InSTILL program to minimally enhanced usual care. Participants will be randomly assigned to receive either the InSTILL program or minimally enhanced usual care. Participants will complete assessments at three timepoints (all) and a brief-exit interview.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Short Stay, Cognitive Impairment, Suicidality, Others

      100 Participants Needed

      Digital Intervention for Depression and Cannabis Use

      Boston, Massachusetts
      The purpose of this study is to examine the feasibility, acceptability, and preliminary efficacy of a digital intervention for co-occurring cannabis use and depression. Participants will be randomized to complete Amplification of Positivity - Cannabis Use (AMP-C) or symptom tracking. The main outcomes will include participant acceptability and usability ratings, completion rates and compliance, positive affect, substance use, and depression severity.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Psychotic Disorder, Bipolar, Suicidal, Others
      Must Not Be Taking:Psychotropic Medications

      80 Participants Needed

      Neuromodulation for Depression and Memory Loss in Older Adults

      Boston, Massachusetts
      This project aims to explore the feasibility and effects of a symptom-specific, brain-circuit-based, home-based neuromodulation therapy for addressing mood and memory symptoms in older adults with major depressive disorder (MDD) in the context of dementia.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:55+

      Key Eligibility Criteria

      Disqualifiers:Seizures, Implanted Devices, Eczema, Others
      Must Not Be Taking:Neuroactive Drugs

      20 Participants Needed

      Cognitive Behavioral Therapy for Smoking Cessation in HIV/AIDS

      Boston, Massachusetts
      Smokers living with HIV represent a major health disparity population in the United States and the world more generally. Major contributing factors to the maintenance and relapse of smoking among smokers living with HIV include increased exposure to multiple stressors associated with HIV, which often exacerbates anxiety/depression. In a previous project, the feasibility, acceptability, and initial efficacy of a 9-session, cognitive-behavioral-based intervention to address smoking cessation by reducing anxiety and depression via specific emotional vulnerabilities (anxiety sensitivity, distress tolerance, and anhedonia) was tested against an enhanced standard of care in a pilot randomized controlled trial (NCT01393301). It was found that when compared to a brief enhanced treatment as usual control, patients in the intervention achieved higher short-term and long-term smoking abstinence rates. In this project, the investigators seek to test this same intervention in a fully powered, 3-arm efficacy/effectiveness trial. The goal of this study is to randomize 180 smokers across three sites to test the efficacy/effectiveness of the intervention at increasing point prevalence abstinence by reducing anxiety and depression at a 1-month follow-up (the end of treatment timepoint/ approximately 1-month post quit day) and a 6-month follow-up (approximately 6-months post quit day).
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      360 Participants Needed

      TMS for Suicide

      Boston, Massachusetts
      This neuroimaging study is a clinical trial investigating the effectiveness of intermittent theta-burst transcranial magnetic stimulation (iTBS-TMS) to the inferior parietal lobule (IPL) in reducing suicide risk in patients with major depressive episode (MDE) or borderline personality disorder (BPD).

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Epilepsy, Alcohol Dependence, Pregnancy, Others

      80 Participants Needed

      Culturally Affirming Therapy for Depression and Anxiety

      Chelsea, Massachusetts
      Aim 1: Expand and adapt the CARE framework to train providers to cultivate a strong early alliance with patients who do not share their background (e.g., mismatched dyads). Aim 2: Establish the feasibility, acceptability, and preliminary effectiveness of the adapted CARE framework in mismatched dyads involving 8 providers and 40 patients receiving 15 sessions of teletherapy. The goal of this clinical trial is to learn if a new CARE intervention works to improve the cultural fit of psychotherapy for diverse populations, even when the therapist and patient do not share the same cultural background. We will refine and test the intervention with a sample of therapists working with Asian American participants receiving short-term individual psychotherapy delivered online. The main questions the study aims to answer are: * Does the CARE framework, adapted for and delivered by therapists specifically trained to work with patients who do not share their background (e.g., mismatched dyads), improve treatment engagement and retention? * Is the CARE framework associated with a) the development of a positive therapeutic relationship between mismatched patient-therapist dyads and b) significant improvements in participants' presenting problems? Participants will: * Receive up to 15 weekly sessions of individual psychotherapy * Complete different online surveys after every session and on a monthly basis
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Severe Symptoms, Other Study, Psychotherapy, Others

      40 Participants Needed

      Online Intervention for Transgender Young Adults' Alcohol Use

      Boston, Massachusetts
      The objective of this study is to learn more about Whole Selves, an interactive online resource ("intervention") to help transgender and/or nonbinary young adults reflect on their experiences and goals related to both alcohol use and romantic relationships. Existing online interventions focused on alcohol use often aren't a good fit for trans/nonbinary people, and existing relationship education programs don't account for how being trans/nonbinary might influence someone's relationships. For these reasons, the investigator is working with trans/nonbinary young adults and other community stakeholders to create a new intervention specifically for trans/nonbinary young adults. The goals of this clinical trial are to: 1. Find out what transgender/nonbinary young adults think of the Whole Selves intervention in order to improve it 2. See whether the Whole Selves intervention seems to work as expected 3. Help the investigator make plans for a bigger clinical trial of the Whole Selves intervention, which could tell us how well it works In this study, participants will use the Whole Selves intervention; complete online surveys about themselves, their romantic relationship experiences, their mental health, their alcohol use; and provide feedback on the Whole Selves intervention.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased
      Age:18 - 30

      Key Eligibility Criteria

      Disqualifiers:Inauthentic Participants

      107 Participants Needed

      123456

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Depression clinical trials in Boston, MA pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Depression clinical trials in Boston, MA work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Depression trials in Boston, MA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Boston, MA for Depression is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Boston, MA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Depression medical study in Boston, MA?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Depression clinical trials in Boston, MA?

      Most recently, we added Online Intervention for Transgender Young Adults' Alcohol Use, Pramipexole vs Escitalopram for Depression in HIV and Advertising Claims for Anxiety and Depression to the Power online platform.

      What do the "Power Preferred" and "SuperSite" badges mean?

      We recognize research clinics with these awards when they are especially responsive to patients who apply through the Power online platform. SuperSite clinics are research sites recognized for a high standard of rapid and thorough follow-up with patient applicants. Meanwhile, Power Preferred clinics are the top 20 across the entire Power platform, recognized for their absolute top patient experience.

      Which clinics have received Power Preferred and SuperSite awards recruiting for Depression trials in Boston, MA?

      The Depression clinics in Boston, MA currently recognized as Power Preferred are: Copley Clinical in Boston, Massachusetts Boston Clinical Trials in Roslindale, Massachusetts Adams Clinical in Watertown, Massachusetts Adams Clinical in Watertown, Massachusetts

      What are the current treatment options for depression?

      Doctors use a stepped-care approach. First, most people try evidence-based talk therapy (such as CBT or interpersonal therapy), an antidepressant medicine (SSRIs are typical), or both, while also improving sleep, exercise and diet. If symptoms persist, the next “step” is to add or switch treatments—e.g., combining two medicines, adding lithium or an antipsychotic, or using brain-stimulation methods like transcranial magnetic stimulation or, for severe cases, electroconvulsive therapy; newer options such as esketamine nasal spray are reserved for treatment-resistant depression. Working with a clinician to review progress every few weeks and adjust the plan is key to finding the right mix.

      When is depression considered severe?

      Doctors call a depressive episode “severe” when almost all of the nine core symptoms are present at high intensity, the person’s daily life has largely shut down (can’t work, study, or manage self-care), or there are high-risk features like active suicidal thoughts, a recent attempt, or hallucinations/false beliefs. On common checklists this usually means a PHQ-9 score of 20 or higher, and it signals the need for urgent, comprehensive care—often a combination of medication, psychotherapy, and sometimes hospitalization. If you or someone you know reaches this point, treat it as an emergency and contact a mental-health professional or call/text 988 (USA) or your local crisis line right away.

      Is it possible to never be depressed again?

      Some people have a single episode of depression and stay well, but the risk of another episode is higher if you stop treatment too soon, have had several episodes before, or still have mild symptoms. You can greatly lower that risk by continuing the treatment that got you better for at least 6–12 months, learning relapse-prevention skills in CBT or mindfulness therapy, keeping regular sleep, exercise, and social routines, and checking in early with a professional if warning signs return. In short, there is no iron-clad guarantee you’ll never be depressed again, but staying on maintenance care and a healthy lifestyle makes long-term wellness much more likely.

      What are the top 3 symptoms of depression?

      Doctors look first for three core signs: 1) a low or hopeless mood that hangs around most of the day, nearly every day; 2) a marked loss of interest or pleasure in things you used to enjoy (called anhedonia); and 3) big changes in body energy—feeling drained, sleeping or eating far more or less than usual. If any of these have lasted two weeks or longer, it’s time to talk with a health professional, because other symptoms can pile on and treatment works best when started early.

      Is depression a chemical imbalance?

      No—depression can’t be pinned on one missing brain chemical. Research shows it arises from a mix of factors: how your brain circuits and several neurotransmitters work, your genes, long-term stress, and life circumstances all interact. Because causes differ from person to person, the most effective care is usually a combination of approaches—medication when needed, talking therapies, and lifestyle changes—worked out with your clinician.

      How many people have untreatable depression?

      Doctors call “untreatable” depression “treatment-resistant depression,” meaning the person has not improved after trying at least two suitable antidepressants. Large studies show this applies to roughly one-quarter to one-third of people with major depression—about 2–3 % of adults overall, or roughly 5–8 million U.S. adults in any given year. Importantly, many still respond to other options such as medication combinations, ketamine/esketamine, transcranial magnetic stimulation, or electroconvulsive therapy.

      How to get out of deep depression?

      Think of recovery as two tracks that run side-by-side. Track 1: get professional help right away—if you ever feel unsafe call 988 (or your local hotline), and with a clinician discuss proven treatments such as CBT, antidepressant medicine, and, when needed, newer options like ketamine, transcranial magnetic stimulation or electroconvulsive therapy. Track 2: reinforce the medical plan daily with mood-boosting basics—consistent exercise, regular sleep, balanced meals, limited alcohol or drugs, and time with supportive people—because these habits make the treatments work better and give you small, sustainable lifts while you heal.

      Why is depression so hard to treat?

      Depression is hard to treat because it isn’t a single disease—each person’s symptoms arise from a unique blend of brain chemistry, genetics, stress, medical issues, and life circumstances—so one-size-fits-all therapies rarely work. Without a blood test to guide choices, clinicians must try treatments sequentially, and roughly one-third of people need several steps or a combination of medication, talk therapy, lifestyle changes, or newer options like ketamine or magnetic stimulation before they feel well. The encouraging news is that persistence with a systematic plan and attention to sleep, exercise, and co-existing conditions allows most patients to eventually reach full recovery.

      What are unhealthy coping mechanisms for depression?

      Unhealthy coping means doing things that give quick relief but actually deepen depression—common examples include using alcohol or other drugs, overeating or not eating, oversleeping or endless screen-scrolling to avoid feelings, cutting or other self-harm, harsh self-talk and rumination, and withdrawing from friends or lashing out at them. These behaviors worsen mood, relationships, and safety; if you notice yourself relying on them, reach out to a trusted person or mental-health professional (or call your local crisis line) and ask about safer skills such as problem-solving steps, scheduled activity, or therapy.

      Is it OK to have clinical depression?

      Yes—having clinical depression isn’t a personal failing; it’s a common medical illness, and recognising it is the first step toward feeling better. What isn’t OK is to face it alone, because untreated depression can worsen and raise the risk of other problems, whereas most people improve with timely care such as talk therapy, medication, or a combination. If symptoms last more than two weeks or include thoughts of self-harm, book a visit with a primary-care doctor or mental-health professional and, in crisis, call 988 (U.S.) or your local emergency number—effective help and recovery are the norm when treatment is started.

      Popular Searches

      By Condition

      Depression Clinical Trials in Massachusetts

      Anxiety Clinical Trials in Massachusetts

      Schizophrenia Clinical Trials in Massachusetts

      ADHD Clinical Trials in Massachusetts

      Bipolar Disorder Clinical Trials in Massachusetts

      Multiple Sclerosis Clinical Trials in Massachusetts

      Autism Clinical Trials in Massachusetts

      Treatment Resistant Depression Clinical Trials in Massachusetts

      Borderline Personality Disorder Clinical Trials in Massachusetts

      Social Anxiety Disorder Clinical Trials in Massachusetts

      Parkinson's Disease Clinical Trials in Massachusetts

      Alzheimer's Disease Clinical Trials in Massachusetts

      By Location

      Clinical Trials near Boston, MA

      Clinical Trials near Worcester, MA

      Clinical Trials near Springfield, MA

      Clinical Trials near Burlington, MA

      Clinical Trials near Fall River, MA

      Clinical Trials near Cambridge, MA

      Clinical Trials near North Dartmouth, MA

      Clinical Trials near Newton, MA

      Clinical Trials near Waltham, MA

      Clinical Trials near Watertown, MA

      Clinical Trials near Belmont, MA

      Clinical Trials near Brockton, MA

      Other People Viewed

      By Subject

      Top Clinical Trials near Boston, MA

      Top Clinical Trials near Boston, MA

      Top Osteoarthritis Clinical Trials near Boston, MA

      Top Osteoporosis Clinical Trials near Boston, MA

      Top Weight Loss Clinical Trials near Boston, MA

      Top Colorectal Cancer Clinical Trials near Boston, MA

      Top Breast Cancer Clinical Trials near Boston, MA

      Top Lung Cancer Clinical Trials near Boston, MA

      Top Prostate Cancer Clinical Trials near Boston, MA

      Top Obsessive Compulsive Disorder Ocd Clinical Trials near Boston, MA

      Top Clinical Trials near Jamaica Plain, MA

      Top Clinical Trials near Attleboro, MA

      By Trial

      Amygdala Neurofeedback for Depression

      Pramipexole for Depression

      Healthy Diet for High Blood Pressure

      Accelerated iTBS for Postpartum Depression

      Deep Brain Stimulation for Treatment-Resistant Depression

      Deep Brain Stimulation for Depression

      Ketamine + Methohexital for Depression

      Transcranial Alternating Current Stimulation for Prenatal Depression

      Standardized Catheterization Assessment for Pulmonary Vein Stenosis

      Carbohydrate Fluids for Postoperative Nausea and Vomiting

      Bias Reduction Training for Pharmacists Prescribing PrEP

      Acceptance and Commitment Therapy for Chronic Post-Surgical Pain

      Related Searches

      Top Depression Clinical Trials near Austin, TX

      Top Depression Clinical Trials near San Antonio, TX

      Top Depression Clinical Trials near San Diego, CA

      Top Depression Clinical Trials near Los Angeles, CA

      Top Glioblastoma Clinical Trials near Houston, TX

      Top Depression Clinical Trials near Baltimore, MD

      Top Insomnia Clinical Trials

      TMS for Depression

      E-cigarettes for Tobacco Use

      Ketamine for Depression

      Diné Parents Taking Action for Autism

      ECC5004 for Type 2 Diabetes